Concurrent factors associated with adherence to adjuvant endocrine therapy among women with non-metastatic breast cancer

被引:1
|
作者
Walsh, Emily A. [1 ]
Walsh, Leah E. [2 ,3 ]
Hernand, Max [2 ]
Horick, Nora [2 ]
Antoni, Michael H. [1 ]
Temel, Jennifer S. [2 ,3 ]
Greer, Joseph A. [2 ,3 ]
Jacobs, Jamie M. [2 ,3 ]
机构
[1] Univ Miami, Dept Psychol, 5665 Ponce de Leon Blvd,Fifth Floor, Coral Gables, FL 33146 USA
[2] Massachusetts Gen Hosp, Boston, MA USA
[3] Harvard Med Sch, Boston, MA USA
关键词
Adjuvant endocrine therapy; Adherence; Breast cancer; Medication-taking self-efficacy; Structural equation modeling; PATIENT-LEVEL METAANALYSIS; OF-POCKET COSTS; SELF-EFFICACY; MEDICATION ADHERENCE; PSYCHOSOCIAL FACTORS; HOSPITAL ANXIETY; HORMONE-THERAPY; DEPRESSION; SURVIVORS; MANAGEMENT;
D O I
10.1007/s11764-024-01556-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Adjuvant endocrine therapy (AET) reduces breast cancer morbidity and mortality, yet women often report suboptimal adherence. Though correlates of AET adherence are well-documented, few studies examine the relative importance of multi-level factors associated with adherence. The aim of this study was to identify factors most strongly associated with AET adherence in women with breast cancer. Methods Between 10/2019 and 6/2021, women (N = 100) with non-metastatic, hormone receptor-positive breast cancer, taking AET who reported AET-related distress enrolled into a clinical trial. Participants completed baseline measures, including the Medication Adherence Rating Scale-5, sociodemographics, and validated measures of anxiety, depression, medication-taking self-efficacy, social support, and treatment satisfaction. We created a latent factor and tested associations between sociodemographic, medical, and psychosocial characteristics and adherence. Associated predictors (p < .10) were entered into a structural model, which was corroborated via multivariate regression modeling. Results A four-indicator latent adherence factor demonstrated good model fit. Participants (M-age = 56.1 years, 91% White) who were unemployed (B = 0.27, SE = 0.13, p = .046) and reported greater treatment convenience (B = 0.01, SE = 0.01, p = .046) reported greater adherence. Scores of participants who reported greater medication-taking self-efficacy (p = .097) and social support (p = .062) approached better adherence. Greater medication-taking self-efficacy (B = 0.08, SE = 0.02, p < .001) and being unemployed (B = 0.28, SE = .14, p = .042) were most strongly associated with greater adherence, inde-pendent of other predictors. Multivariate modeling confirmed similar findings. Conclusions Medication-taking self-efficacy and employment status were associated with AET adherence above other related factors. Implications for Cancer Survivors Enhancing patients' confidence in their ability to take AET for breast cancer may represent an important intervention target to boost adherence
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer
    Pernin, Victor
    Belin, Lisa
    Cottu, Paul
    Bontemps, Patrick
    Lemanski, Claire
    De La Lande, Brigitte
    Baumann, Pierre
    Missohou, Fernand
    Levy, Christelle
    Peignaux, Karine
    Bougnoux, Pierre
    Denis, Fabrice
    Bollet, Marc
    Dendale, Remi
    Vago, Nora Ady
    Campana, Francois
    Fourquet, Alain
    Kirova, Youlia M.
    BREAST, 2014, 23 (06): : 816 - 820
  • [22] Medication delivery factors and adjuvant endocrine therapy adherence in breast cancer
    Neuner, Joan M.
    Fergestrom, Nicole
    Pezzin, Liliana E.
    Laud, Purushottam W.
    Ruddy, Kathryn J.
    Winn, Aaron N.
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 197 (01) : 223 - 233
  • [23] Medication delivery factors and adjuvant endocrine therapy adherence in breast cancer
    Joan M. Neuner
    Nicole Fergestrom
    Liliana E. Pezzin
    Purushottam W. Laud
    Kathryn J. Ruddy
    Aaron N. Winn
    Breast Cancer Research and Treatment, 2023, 197 : 223 - 233
  • [24] Primary non-adherence to adjuvant endocrine therapy in older women with breast cancer.
    Tchuente, Vanina
    Stern, Donna
    Prchal, Jaroslav
    Martin, Judy
    Tamblyn, Robyn
    Meguerditchian, Ari N.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (27)
  • [25] Factors associated with adherence to adjuvant endocrine therapy in patients with hormone receptor positive breast cancer
    Kim, Jongjin
    Han, Wonshik
    Moon, Hyeong-Gon
    Kim, Min Kyoon
    Lee, Eunshin
    Yoo, Tae-Kyung
    Lee, Han-Byoel
    Kang, Young Joon
    Kim, Yun-Gyoung
    Kim, Tae Ryung
    Noh, Dong Young
    CANCER RESEARCH, 2015, 75
  • [26] Oncologists' perspectives on adherence/non-adherence to adjuvant endocrine therapy and management strategies in women with breast cancer
    Eraso, Yolanda
    PATIENT PREFERENCE AND ADHERENCE, 2019, 13 : 1311 - 1323
  • [27] PSYCHOSOCIAL CORRELATES OF NON-ADHERENCE TO ADJUVANT ENDOCRINE THERAPY AMONG BREAST CANCER SURVIVORS
    Ream, Molly
    Taub, Chloe
    Fisher, Hannah
    Jacobs, Jamie
    Blomberg, Bonnie
    Carver, Charles
    Antoni, Michael H.
    ANNALS OF BEHAVIORAL MEDICINE, 2019, 53 : S612 - S612
  • [28] COPING AND ENDOCRINE THERAPY ADHERENCE AMONG WOMEN WITH BREAST CANCER
    Bright, Emma E.
    Stanton, Annette L.
    ANNALS OF BEHAVIORAL MEDICINE, 2017, 51 : S89 - S89
  • [29] Knowledge of Cancer Stage Among Women With Non-Metastatic Breast Cancer
    Hinchey, Jenna
    Goldberg, Jessica
    Linsky, Sarah
    Linsky, Rebecca
    Schulman-Green, Dena
    NURSING RESEARCH, 2013, 62 (02) : E75 - E76
  • [30] Trajectories of adherence to adjuvant endocrine therapy for 5 years in women with breast cancer
    Memoli, V.
    Lailler, G.
    Le-Bihan, C.
    Bendiane, M. K.
    Lauzier, S.
    Mancini, J.
    Bousquet, P. J.
    Bouhnik, A. D.
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2020, 30